Latest Pharmaceuticals News

Page 27 of 35
Mayne Pharma Group has acknowledged a delayed filing of a director's interest notice due to administrative oversight and is taking steps to reinforce compliance with ASX disclosure rules.
Ada Torres
Ada Torres
12 May 2025
Acrux Limited, partnering with TruPharma, has introduced its Dapsone 7.5% Gel in the US, featuring a unique tube packaging that aims to improve patient convenience and reduce environmental impact.
Victor Sage
Victor Sage
9 May 2025
Neuren Pharmaceuticals reports a robust 11% rise in DAYBUE™ US net sales for Q1 2025, alongside a 17% jump in royalty income, setting the stage for an anticipated European market entry in early 2026.
Victor Sage
Victor Sage
8 May 2025
Algorae Pharmaceuticals has partnered with Peter MacCallum Cancer Centre to validate AI-predicted drug combinations across multiple cancer types, aiming to accelerate its oncology pipeline development.
Ada Torres
Ada Torres
8 May 2025
Nyrada’s experimental drug NYR-BI03 shows promising cardioprotective and anti-arrhythmic effects in animal models, reinforcing its potential as a treatment for acute myocardial infarction.
Ada Torres
Ada Torres
8 May 2025
LTR Pharma has partnered with Strategic Drug Solutions to co-develop OROFLOW®, a novel intranasal spray aimed at providing fast symptom relief for Oesophageal Motility Disorders, tapping into a growing $4.5 billion global market.
Ada Torres
Ada Torres
8 May 2025
Mayne Pharma has announced the expiration of the US antitrust waiting period, a critical step forward in Cosette Pharmaceuticals' proposed acquisition. The transaction now moves closer to completion, pending other regulatory and shareholder approvals.
Ada Torres
Ada Torres
7 May 2025
Acrux Limited has appointed John Warmbrunn as its new CEO and Managing Director, signaling a strategic push for international expansion and product development starting June 2025.
Ada Torres
Ada Torres
7 May 2025
CLINUVEL Pharmaceuticals has completed recruitment for its Phase III trial of SCENESSE® in vitiligo patients with darker skin types, setting the stage for first results in late 2026. Early clinical observations suggest promising repigmentation outcomes.
Ada Torres
Ada Torres
7 May 2025
Nyrada Inc. has cleared the Safety Review Committee’s scrutiny for its Phase I clinical trial, progressing to the third dosing cohort of its promising neuroprotective and cardioprotective drug candidate NYR-BI03.
Ada Torres
Ada Torres
2 May 2025
Recce Pharmaceuticals reports strong Phase II clinical trial results for its topical anti-infective R327G, achieving a 93% efficacy rate in treating ABSSSI, alongside a significant capital raise to fund upcoming Phase III trials.
Ada Torres
Ada Torres
30 Apr 2025
Avecho Biotechnology has inked a decade-long exclusive licensing agreement with Sandoz for its pharmaceutical-grade cannabidiol capsule targeting insomnia in Australia, backed by a US$3 million upfront payment and promising milestone and royalty streams.
Victor Sage
Victor Sage
30 Apr 2025